

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

AIM2 inflammasome activation in astrocytes occurs during the late phase of EAE

William E. Barclay^a, M. Elizabeth Deerhake^a, Makoto Inoue^{a,b}, Toshiaki Nonaka^a, Kengo Nozaki^a, Nathan A. Luzum^a, Nupur Aggarwal^a, Edward A. Miao^{a,c}, Mari L. Shinohara^{a,c,*}

^aDepartment of Immunology, Duke University Medical School. Durham, NC 27710.

^bDepartment of Comparative Biosciences, University of Illinois at Urbana-Champaign, Urbana, IL 61802.

^cDepartment of Molecular Genetics and Microbiology, Duke University Medical School. Durham, NC 27710.

***Corresponding Author:** Mari L. Shinohara
mari.shinohara@duke.edu

Keywords: Experimental autoimmune encephalomyelitis (EAE); AIM2 inflammasome; astrocytes; ASC specks

26 **ABSTRACT**

27 Inflammasomes are a class of innate immune signaling platforms that activate in response
28 to an array of cellular damage and pathogens. Inflammasomes promote inflammation under many
29 circumstances to enhance immunity against pathogens and inflammatory responses through their
30 effector cytokines, IL-1 β and IL-18. Multiple sclerosis and its animal model, experimental
31 autoimmune encephalomyelitis (EAE), are such autoimmune conditions influenced by
32 inflammasomes. Despite work investigating inflammasomes during EAE, little remains known
33 concerning the role of inflammasomes in the central nervous system (CNS) during the disease.
34 Here we use multiple genetically modified mouse models to monitor activated inflammasomes *in*
35 *situ* based on ASC oligomerization in the spinal cord. Using inflammasome reporter mice, we
36 found heightened inflammasome activation in astrocytes after the disease peak. In contrast,
37 microglia and CNS-infiltrated myeloid cells had few activated inflammasomes in the CNS during
38 EAE. Astrocyte inflammasome activation was dependent on AIM2, but low IL-1 β expression and
39 no significant signs of cell death were found in astrocytes during EAE. Thus, the AIM2
40 inflammasome activation in astrocytes may have a distinct role from traditional inflammasome-
41 mediated inflammation.
42

43 **SIGNIFICANCE STATEMENT**

44 Inflammasome activation in the peripheral immune system is pathogenic in multiple
45 sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE).
46 However, inflammasome activity in the central nervous system (CNS) is largely unexplored. Here,
47 we used genetically modified mice to determine inflammasome activation in the CNS during EAE.
48 Our data indicated heightened AIM2 inflammasome activation in astrocytes after the disease
49 peak. Unexpectedly, neither CNS-infiltrated myeloid cells nor microglia were the primary cells with
50 activated inflammasomes in SC during EAE. Despite AIM2 inflammasome activation, astrocytes
51 did not undergo apparent cell death and produced little of the proinflammatory cytokine, IL-1 β ,
52 during EAE. This study showed that CNS inflammasome activation occurs during EAE without
53 associating with IL-1 β -mediated inflammation.
54

55 **INTRODUCTION**

56 Multiple sclerosis (MS) and its mouse model, experimental autoimmune encephalomyelitis
57 (EAE), are demyelinating neurodegenerative diseases punctuated by inflammatory immune
58 reactions in the central nervous system (CNS). Inflammasomes are sensors of a wide range of
59 microbe-associated molecular patterns (MAMPs) and damage-associated molecular patterns
60 (DAMPs) and induce inflammation (1). In EAE, the NLRP3 inflammasome has a particularly well-
61 documented role in the peripheral immune system in promoting immune cell recruitment to the
62 CNS through the generation of the inflammatory cytokines IL-1 β and IL-18 by peripheral myeloid
63 cells (2-5). However, despite much work centered on inflammasomes in the peripheral immune
64 response, the role of inflammasomes in the CNS is significantly less understood.

65 Inflammasomes are distinct from other PRRs in mode of signaling and downstream
66 effector function. First, a sensor (*e.g.*, NLRP3, AIM2) forms a scaffold, to which the inflammasome
67 adaptor ASC binds and polymerizes (called the “ASC speck”). Pro-caspase-1 associates with the
68 polymer, then self-cleaves to become proteolytically active caspase-1, which further activates
69 downstream substrates, including pro-IL-1 β , pro-IL-18, and the pore-forming protein, gasdermin-
70 D (GSDMD). Cleaved GSDMD forms a pore in cellular membranes and induces pyroptosis,
71 resulting in a release of mature IL-1 β and IL-18 to the extracellular space. In MS, genetic variation
72 in inflammasome signaling pathways was reported (6, 7). Particularly, the NLRP3 inflammasome
73 was demonstrated to be a prognostic factor and a therapeutic target in primary progressive MS
74 (8). In EAE, NLRP3 and ASC are necessary for passive and standard (“Type-A”) active EAE (2-

75 4). NLRP3 inflammasome activation in macrophages and dendritic cells in secondary lymphoid
76 organs results in IL-1 β and IL-18 release, which induces expression of chemokines and their
77 receptors required for leukocyte CNS entry (2). We have also demonstrated that the NLRP3
78 inflammasome can be dispensable for EAE induction if the innate immune system is strongly
79 activated with aggressive immunization schemes (“Type-B EAE”)(9).

80 As inflammasome activation is a post-translational process, the expression of
81 inflammasome components does not necessarily indicate their activation. Thus, separately
82 assessing both expression and activation of inflammasomes is critical. Recent studies indicated
83 that microglia, astrocytes, and neurons can activate inflammasomes; and most identification was
84 performed *ex vivo* (8, 10-17). However, defining inflammasome activation *in situ* is critical
85 because CNS-resident cells significantly alter their behavior once isolated from tissues. So far,
86 only a limited number of studies has demonstrated unequivocal activation of inflammasomes *in*
87 *situ* in the CNS (10-12).

88 In this report, we identified activated inflammasomes in the CNS during EAE using the
89 ASC-Citrine mouse line, which allows *in situ* detection of activated inflammasomes (18). Our study
90 identified maximal inflammasome activation in the spinal cord (SC) after the EAE peak, which
91 contrasts with the inguinal lymph nodes (iLNs), in which inflammasome activation was present at
92 pre-symptomatic disease. Unexpectedly, neither microglia nor CNS-infiltrated myeloid cells were
93 the primary cells with activated inflammasomes in SC during EAE. Instead, we detected
94 inflammasome activation mainly in astrocytes and limited inflammasome activation in motor
95 neurons. Furthermore, we found that the AIM2 inflammasome is activated in astrocytes during
96 EAE. However, even with AIM2 inflammasome activation, astrocytes did not clearly undergo cell
97 death and have poor *I11b* gene expression, suggesting the possibility that AIM2 inflammasome
98 activation in astrocytes serves a different purpose than traditional inflammasome-mediated
99 inflammation.

100

101 RESULTS

102

103 Inflammasome activation in the spinal cord at a late stage of EAE

104 Inflammasome signaling is critical to EAE development in the peripheral lymphoid organs
105 (2-5, 9). Yet, the extent and spatiotemporal distribution of inflammasome activation in the CNS
106 during EAE is largely unknown. Classically, detection of inflammasome activation is performed
107 by identifying cleaved caspase-1 by Western blotting (WB), which cannot be applied *in situ*.
108 Therefore, we used a different molecular signature of inflammasome activation – the
109 oligomerization of ASC, microscopically observed as the “ASC speck.” In this study, we used
110 inflammasome activation reporter mice, which express ASC fused to a fluorescent Citrine protein
111 (ASC-Citrine)(18). The ASC-Citrine reporter allows *in situ* detection of active inflammasomes by
112 visualization of ASC specks (12, 18) (**Fig. S1A**), and the presence of the reporter did not alter
113 disease course of EAE (**Fig. 1A**). The ASC-Citrine reporter was validated for use in tissue by
114 immunostaining against ASC in live spleen slice cultures following NLRP3 inflammasome
115 activation (**Fig. S1A**).

116 Before evaluating inflammasome activation in the CNS, we first visualized and quantified
117 ASC specks in the iLNs as the primary site of immune reaction to EAE induction. ASC specks
118 were detected at 3 days post induction (dpi) of EAE (**Fig. 1B, C**), which is well before the disease
119 onset, and continually detected until 9-dpi (**Fig. 1C**). However, ASC specks were almost
120 undetectable by the point of disease peak (16-dpi) and after (**Fig. 1C**). The cervical lymph nodes
121 (cLN) have also been noted as a site of primary immune reaction in some models of EAE (19,
122 20), but few ASC specks were detected there throughout disease (**Fig. S1B**). The spinal cord
123 (SC) of ASC-Citrine mice exhibited a much higher number of ASC specks than the iLNs (**Fig. 1D-**

124 **F)** with a significant increase in the number of ASC specks in the later phase of EAE at 30-dpi
125 (**Fig. 1D, F**). Further, in addition to ASC specks, we also observed atypical fiber-like ASC-Citrine
126 signals, which we termed “ASC strings,” unique to the CNS (**Fig. 1G**). While different in
127 magnitude, both ASC specks and ASC strings appeared with the largest increases at the later
128 phase of disease, around 30-dpi (**Fig. 1F, H**). Due to the abundance of ASC specks and strings
129 at 30-dpi, all subsequent analyses in SC were at 30-dpi, unless otherwise stated. This
130 quantification was also performed manually, and all subsequent ASC speck and string
131 quantification was performed using the Imaris software.

132 We have previously shown a sub-type of EAE (Type-B EAE) which does not require the
133 NLRP3 inflammasome in the peripheral lymphoid organs to develop EAE (9). In the CNS, Type-
134 A and Type-B EAE had comparable numbers of ASC specks (**Fig. S1C, D**), suggesting the more
135 consistent connection of EAE severity and active inflammasome in the CNS than in the periphery.
136 In sum, these results suggest that inflammasomes are activated in the SC during both Type-A
137 and Type-B EAE and that their activation is heightened after peak disease.

138

139 **Inflammasome activation in non-BM-derived cells in the spinal cord**

140 Because we identified inflammasome activation in the CNS during EAE, the role of ASC
141 in non-hematopoietic cells was investigated with a bone marrow (BM) chimera approach using
142 CD45.1 congenic donor mice. We compared two groups of BM chimeras, generated by adoptively
143 transferring WT BM cells to either WT or *Pycard*^{-/-} (ASC knockout) recipients (the extent of
144 reconstitution is shown in **Fig. S2A**). Compared to WT recipients, *Pycard*^{-/-} recipients
145 demonstrated milder EAE after the disease peak (**Fig. 2A-C**), suggesting that ASC in non-
146 hematopoietic cells impacted EAE severity after the disease peak. Next, we sought to determine
147 if CNS-infiltrated cells possess activated inflammasomes in the SC during EAE. Two groups of
148 BM chimeras were compared; one group with ASC-Citrine BM donor cells to wild-type (WT)
149 recipients and the other with WT BM cells to ASC-Citrine recipients. Reconstitution of
150 approximately 90% of BM cells were confirmed (**Fig. S2B**) and no impact of ASC-Citrine
151 expression on EAE development was confirmed (**Fig. S2C**). ASC specks were identified in the
152 iLNs of WT recipients reconstituted with ASC-Citrine BM (**Fig. 2D, E**). However, unexpectedly,
153 the mice showed no ASC specks and strings in the SC (**Fig. 2F-H; S2D**). In contrast, ASC specks
154 and strings were identified in the SC of ASC-Citrine recipients transferred with WT BM cells (**Fig.**
155 **2F-H**). This suggests that the source of inflammasome activation is CNS-resident cells in the SC.

156

157 **Inflammasome activation in CNS during EAE in astrocytes**

158 We next sought to identify CNS-resident cells with activated inflammasomes during EAE.
159 ASC specks and strings were identified, and then cell types were assigned by counterstaining to
160 identify microglia (TMEM119), astrocytes (GFAP or ALDH1L1), neurons (NeuN), oligodendrocyte
161 precursor cells (NG2), or mature oligodendrocytes (MBP) (**Fig. 3A-C; S2E, F**). The majority of
162 ASC specks and strings were found in astrocytes, while a small number were classified as
163 microglial and neuronal (**Fig. 3D-F**). Few ASC specks or strings were detected in oligodendrocyte
164 precursor cells (OPCs) or mature oligodendrocytes (**Fig. S2G, H**). In neurons, all ASC specks
165 were found in cell bodies of ChAT⁺ alpha motor neurons (ChAT⁺NeuN⁺) in the ventral horn (VH),
166 but these neuronal ASC specks did not increase during EAE (**Fig. S2I**).

167 We further validated these findings with a cell type-specific ASC-Citrine reporter approach
168 by using *Asc-Citrine*^{LSL} mice, which retain an LSL cassette upstream of the ASC-Citrine construct.
169 To express ASC-Citrine in astrocytes and neurons in a cell type-specific manner, we used
170 *Gfap*^{Cre};*Asc-Citrine*^{LSL} and *Syn1*^{Cre};*Asc-Citrine*^{LSL} mice, respectively. For microglia-specific ASC-
171 Citrine expression, we used *Cx3cr1*^{CreERT2};*Asc-Citrine*^{LSL} mice treated with tamoxifen (TAM) with
172 a six-week “wash out” period to exclude ASC-citrine expression in myeloid cells other than
173 microglia (**Fig. S3A**) by taking an advantage of the long half-life of microglia (gating strategy to

174 evaluate microglia is shown in **Fig. S3B**). We considered that using the microglia-specific ASC-
175 Citrine reporter mice was critical because the expression level of Tmem119, used in **Fig. 3A-F**,
176 decreases as EAE progresses (21) and may confound some image analysis. No alteration in EAE
177 severity was confirmed in the group of mutant mice expressing Cre in targeted cell types (**Fig.**
178 **S3C-E**). The SC of these mutant mice was analyzed during EAE by confocal microscopy (**Fig.**
179 **4A-C**). Again, a high number of ASC specks and strings were confirmed in astrocytes by using
180 the *Gfap^{Cre};Asc-Citrine^{LSL}* mice, while few ASC specks or strings were identified in microglia (**Fig.**
181 **4D, E**). Neurons also showed a consistent but small number of ASC specks (**Fig. 4D, E**).
182 Nonetheless, these data mirrored the results by antibody counterstaining in **Fig. 3A-G**, strongly
183 indicating that inflammasome activation is predominantly in astrocytes during EAE.
184

185 **Limited induction of IL-1 β -mediated inflammation by astrocytes during EAE**

186 In EAE, astrocytes become activated in a process called astrogliosis; these activated cells
187 gain a pro-inflammatory phenotype and are termed “reactive astrocytes” (22, 23). Here we
188 investigated whether astrogliosis correlates with inflammasome activation. Astrogliosis was
189 detected as increased GFAP intensity at 30-dpi (**Fig. 5A, B**), but GFAP intensity did not correlate
190 on a per cell basis with the presence of ASC specks (**Fig. 5C, D**). We similarly found no correlation
191 between inflammasome activation and individual acquisition of the neurotoxic “A1” reactive
192 astrocyte phenotype (24, 25), based on the A1-astrocyte marker C3d (26), although C3d
193 expression was enhanced in astrocytes in aggregate during EAE (**Fig. 5C, E**).

194 To evaluate astrocyte gene expression during EAE, we first re-analyzed publicly available
195 data obtained with a *Gfap^{Cre}*-driven RiboTag mouse system, which allows purification of astrocyte-
196 specific RNA (GSE100329)(27). Gene expression in total SC and SC astrocytes were compared
197 between naïve and 30-dpi EAE mice. We found low expression of *Il1b* and genes encoding
198 inflammasome sensor proteins (**Fig. S4A**). Expression levels of *Il18* and *Casp1* were enriched in
199 astrocytes independent of EAE (**Fig. S4A**). To validate this data, we evaluated gene expression
200 by RT-qPCR in total SC cells and astrocytes enriched by bead selection from naïve and 30-dpi
201 EAE mice. Astrocyte-enriched cells showed generally low expression of genes encoding proteins
202 related to inflammasomes even during EAE. Notably, the expression of *Il1b*, *Casp-1*, and *Gsdmd*
203 was significantly lower in astrocyte-enriched cells than total SC cells (normalized to *Il1b* and
204 *Casp1* expression in naïve total SC cells for **Fig. 6A** and **B**, respectively). In the qPCR analyses,
205 a majority of genes shown in **Fig. S4A** had mRNA levels that were close to the detection limit,
206 despite reasonably high total RNA amounts, suggesting the general low expression of
207 inflammasome-related genes in astrocytes. Under the low gene expression, we did not observe
208 astrocyte enrichment of *Il18* and *Casp1* expression, as suggested in the RiboTag data (**Fig. S4A**).
209 This was consistent with the limited detection of the inflammasome-related proteins caspase-1,
210 IL-1 β , and GSDMD in SC astrocytes of either naïve mice or mice with EAE 30 dpi by
211 immunostaining, despite robust detection in the spleen (**Fig. S4B-G**). However, mild expression
212 of GSDMD was detected in SC astrocytes following EAE induction (**Fig. S4D, G**). Next, we
213 performed Western blotting (WB) to evaluate protein levels and inflammasome activation *in vitro*.
214 Here, we used the C8-S astrocyte cell line due to the difficulty of culturing primary astrocytes,
215 especially without altering their character in tissue culture settings. We compared C8-S to bone
216 marrow-derived macrophages (BMDMs) as a positive control. We stimulated the NLRP3 or AIM2
217 inflammasome with nigericin or poly(dA:dT)-liposomes, respectively, after ultrapure LPS pre-
218 treatment. Culture supernatants of C8-S showed a scarcity of cleaved caspase-1, IL-1 β and IL-
219 18 (**Fig. 6C; S5A-C**). Notably, C8-S cell lysates also showed greatly reduced pro-caspase-1, pro-
220 IL-1 β , GSDMD-FL, and GSDMD-NT, compared to BMDMs (**Fig. 6C; S5D-H**). These results
221 suggest that astrocytes do not induce inflammation, mediated particularly by IL-1 β as
222 macrophages do.

223 Next, we investigated whether astrocytes with ASC specks or strings undergo cell death
224 during EAE. We attempted to assess general cell death by TUNEL staining. TUNEL⁺ cells were
225 present in the periphery of the SC at 30-dpi EAE, though no TUNEL⁺ astrocytes were detected
226 (Fig. 6D, E), consistent with previous data demonstrating that astrocytes do not undergo
227 significant cell death during EAE (28). Although normally not associated with canonical
228 inflammasomes, we found enriched active caspase-3 (CC3) in astrocytes with active
229 inflammasomes in both ASC-Citrine (Fig. 6F, G) and *Gfap*^{Cre};*Asc-Citrine*^{LSL} (Fig. S5I) mice,
230 suggesting a possible connection between inflammasomes and caspase-3 activation in
231 astrocytes. In summary, inflammasomes activation in astrocytes does not appear to lead to typical
232 outcomes of inflammasome activation as seen in myeloid cells.
233

234 AIM2 facilitates inflammasome activation in the CNS during EAE

235 To further assess which inflammasome is activated in astrocytes during EAE, we selected
236 NLRP3 and AIM2 among the inflammasome sensors based on their expression by astrocytes
237 during EAE by the Ribotag raw transcript data (Fig. S4A). As *Nlrp3*^{-/-} mice are resistant to
238 standard EAE, we used the Type-B EAE model to induce EAE in the *Nlrp3*^{-/-} background (3, 9)
239 and confirmed that ASC-Citrine mice and *Nlrp3*^{-/-};*ASC-Citrine* developed similar disease course
240 and severity, as expected (Fig. S6A). Here, *Nlrp3*^{-/-};*ASC-Citrine* mice still showed comparable
241 numbers of ASC specks with ASC-Citrine mice (Fig. 7A, B), suggesting that NLRP3 is
242 dispensable in CNS inflammasome activation during EAE. Next, we tested the AIM2
243 inflammasome. Congruent with recent reports (13, 29), we found AIM2 to be protective in EAE,
244 as demonstrated by more severe disease in *Aim2*^{-/-} mice predominantly after disease peak, when
245 induced with a low dose adjuvant (50 µg *Mtb*/mouse) (Fig. 7C, D). The immune phenotype of
246 *Aim2*^{-/-} mice in SC, iLN, and spleen at 16-dpi did not show statistically significant changes
247 compared to WT mice, although a trend of increased T cells, microglia, and macrophages were
248 observed, possibly reflecting the disease severity of *Aim2*^{-/-} mice (Fig. S6B-D), together with
249 enhanced astrogliosis (Fig. S6E, 7E).

250 Next, we investigated the role of the AIM2 in astrocyte inflammasome activation during
251 EAE. To do so, we sought an EAE condition for *Aim2*^{-/-} mice to develop comparable EAE severity.
252 Despite increased EAE severity in *Aim2*^{-/-} mice, an increased adjuvant dose (200 µg *Mtb*/mouse)
253 elicited comparable EAE scores between WT and *Aim2*^{-/-} mice (Fig. 7F). Here, a strong gene
254 dosage effect of AIM2 on ASC speck formation was observed (Fig. 7G, H), strongly suggesting
255 that inflammasome activation in astrocytes *in vivo* indeed requires AIM2.
256

257

258 DISCUSSION

259 Many studies show gene and protein expression of inflammasome components in the
260 CNS *in vivo*, but a few have evaluated *bona fide* inflammasome activation. This study used
261 reporter mice to detect activated inflammasomes *in situ* in a cell-type-specific manner in the CNS
262 during EAE. Using the ASC-Citrine mice, we identified AIM2 inflammasome activation after
263 disease peak mainly in astrocytes in the SC of EAE mice. Unexpectedly, we detected limited or
264 no inflammasome activation in CNS-infiltrated myeloid cells or microglia.

265 Previous studies suggested inflammasome activation in CNS-resident cells during EAE
266 and MS, but these studies evaluated inflammasome activation of microglia or astrocytes in tissue
267 culture (8, 13-17). A few studies demonstrated inflammasome activation in the CNS during EAE
268 *in situ*. One such study showed ASC specks in Iba-1⁺ cells, suggested to be microglia, in the
269 hippocampus of EAE mice, but the investigation was not extended to astrocytes (11). Another
270 study suggested caspase-8-mediated noncanonical NLRP3 inflammasome activation in microglia
271 in the SC of EAE mice based on caspase-8-FLICA staining of tissue sections (30). It is possible

272 that a small number of microglia may activate inflammasomes, although our data showed that
273 significantly more inflammasome activation occurs at 30-dpi in astrocytes.

274 We and other groups have shown that the NLRP3 inflammasome is detrimental in EAE.
275 However, recent studies (13, 29) and our results demonstrate that AIM2 can play a protective
276 role. Chou et al. demonstrated that AIM2 suppresses EAE by promoting T_{reg} stability in an
277 inflammasome-independent fashion (29). Similarly, the study by Ma et al. demonstrated a
278 protective role of AIM2 through another inflammasome-independent mechanism targeting the
279 DNA-PK-AKT3 pathway (13). Using *Aim2^{fl/fl};Gfap^{Cre}* mice, Ma et al. evaluated the disease severity
280 in Type-B EAE and found that astrocyte-specific *Aim2* depletion did not change the disease
281 severity (13). Of note, the study did not evaluate the disease score beyond 18 dpi (around disease
282 peak) (13). However, our data indicated numbers of ASC specks both in naïve and 16-dpi EAE
283 mice (around disease peak) are basal, while the most significant increase was observed on 30-
284 dpi. Additionally, Ma et al. induced Type-B EAE in *Aim2^{fl/fl};Gfap^{Cre}* mice (13) but we did not. Thus,
285 intensity of EAE induction possibly affects the involvement of AIM2 in EAE too, as we
286 demonstrated that increased adjuvant upon induction of EAE blunts the impact of AIM2 on
287 disease (**Fig. 7F**). A long-term evaluation of astrocyte-specific AIM2 knockout mice and
288 elucidating an impact of EAE induction methods will merit further understanding the protective
289 role of the AIM2 inflammasomes in astrocytes.

290 Using the ASC-Citrine mouse model, two recent reports have identified ASC specks in the
291 cerebellum during development (12) and in retinal astrocytes during ocular hypertension injury
292 (31). Notably, one of the studies also showed the ASC specks in naïve animals (12), mirroring
293 our finding of ASC specks in naïve SC (**Fig. 1D, F**). Further, the ASC specks in the study are
294 AIM2-dependent, and the AIM2 inflammasome contributes to normal brain development (12).
295 Therefore, the function of the AIM2 inflammasome in the CNS may be intrinsically different from
296 that in peripheral myeloid cells, which are equipped to induce inflammation. For example, our
297 study indicated that astrocytes express little *I11b* mRNA and exhibit no marked cell death upon
298 inflammasome activation in EAE, suggesting that inflammasome activation in astrocytes *in vivo*
299 may have biological implications other than enhancing inflammation.

300 In this study, we observed ASC strings, which were unique to the CNS *in vivo*. However,
301 some *ex vivo* studies have shown a similar ASC string-like structure. “ASC filaments” have been
302 documented *ex vivo* with mutant ASC (32) or with ASC CARD domain blockade or deletion (33-
303 35). An ASC isoform (ASC-c) also generates ASC filaments in human cells and appears to be
304 expressed in mice, at least in the J774A.1 cell line (36). It is not known how astrocytes generate
305 ASC strings, but several possibilities exist, such as potential astrocyte-specific expression of the
306 ASC-c isoform or interaction of inflammasome components with astrocyte-specific molecules. For
307 example, GFAP and vimentin bind together as part of the astrocyte intermediate filament network
308 (37); and vimentin is known to interact with inflammasome components, such as caspase-1 (38).
309 Thus, a possible physical association of GFAP to inflammasome components might explain the
310 appearance of ASC strings in the highly ramified astrocyte.

311 We identified activated caspase-3 in astrocytes with ASC specks in the absence of cell
312 death. Caspases, including caspase-3, possess critical functions outside of induction of cell death
313 (39). Specifically, non-apoptotic caspase-3 activation is involved in the differentiation of numerous
314 cell types, such as monocytes, neurons, and hematopoietic stem cells (39). Also, neurons, which
315 derive from similar progenitors to astrocytes, rely on caspase-3 for dendrite and axon remodeling
316 (40, 41) and synaptic plasticity (42). Caspase-3 activation in astrocytes is also associated with
317 astrogliosis and not cell death (43-46). Specifically, caspase-3 activation in astrocytes is
318 associated with cytoskeletal remodeling in a kainic-acid induced neurodegeneration model (44),
319 reactive astrocytes following excitotoxic N-Methyl-D-aspartate (NMDA)-induced
320 neurodegeneration (46), and GFAP cleavage in an Alzheimer’s disease model (43). Indeed, our
321 data suggested the involvement of AIM2 inflammasome in caspase-3 activation and GFAP
322 cleavage. The non-apoptotic activation of caspase-3 in astrocytes is inducible *in vitro*, and

323 promotes expression of glutamate synthase and basic fibroblast growth factor-mediated by
324 astrogliosis (45). Our study now connects inflammasome activation in astrocytes to caspase-3
325 activation and so warrants further study into the role of caspase-3 in astrogliosis.

326 The AIM2 inflammasome is activated by double-stranded DNA (dsDNA) derived not only
327 from microbes but also from endogenous sources as a sentinel of genotoxic stress and DNA
328 damage. The AIM2 inflammasome protects from gastrointestinal toxicity and hematopoietic failure
329 in total-body irradiation (47), which triggers DNA double-strand breaks (47) and nuclear
330 membrane disruption (48). Indeed, the detection of dsDNA by AIM2 is required for normal
331 neurodevelopment during periods of proliferative stress in neurons of the CNS (12). These studies
332 demonstrated AIM2-mediated protection from damage and even limiting inflammation, which
333 positions the AIM2 inflammasome separately from the classical understanding of other
334 inflammasomes, such as the NLRP3 inflammasome. Opposing outcomes of EAE severity in the
335 absence of AIM2 versus ASC, as well as our results demonstrating a detrimental role of ASC in
336 non-hematopoietic cells (**Fig. 2A-C**), are intriguing; however perhaps not surprising, as ASC is
337 the common adaptor to other inflammasomes, including the NLRP3 inflammasome, which is
338 pathogenic during EAE. Thus, the pathogenic impact of the NLRP3 inflammasome (and perhaps
339 the Pyrin inflammasome (49)) on EAE potentially supersedes the functions of the AIM2
340 inflammasome in an ASC-deficient animal.

341 In conclusion, our study demonstrates astrocyte AIM2 inflammasome activation without
342 eliciting IL-1 β -mediated inflammation in the late phase of EAE. This study expands our
343 understanding of astrocytes in EAE and warrants further investigation of non-inflammatory
344 functions of the AIM2 inflammasome in astrocytes during neuroinflammation.

345

346

347 MATERIALS AND METHODS

348

349 **Animals.** We used mice of the C57BL/6 genetic background of both sexes aged 8-12 weeks old,
350 unless otherwise noted. Because we did not identify sex differences in our experiments, both
351 male and female were equally represented in our experiments. The ASC-Citrine mice were
352 generated and gifted by Dr. Douglas Golenbock (University of Massachusetts Medical School).
353 The *Pycard*^{-/-} and *Nlrp3*^{-/-} mice were initially obtained from Genentech. The following mice are
354 from The Jackson Laboratory; *Cx3cr1*^{CreERT2} (#020940) *Gfap*^{Cre} (#012886), *Asc-Citrine*^{LSL}
355 (#030743), *Syn1*^{Cre} (#003966), and *Aim2*^{-/-} (# 013144). *Gfap*^{Cre} and *Syn1*^{Cre} mice were used as
356 heterozygotes. Mice for all experiments were housed in a specific pathogen-free environment. All
357 animal experiments included in this study were approved by the Institutional Animal Care and Use
358 Committee of Duke University.

359

360 **EAE induction and scoring.** Mice were immunized with CFA/MOG emulsion in the lower back
361 on day 0. The emulsion was prepared by mixing MOG₃₅₋₅₅ peptide (United Biosystems, Cat#
362 U104628) and complete Freund's adjuvant (Sigma-Aldrich, Cat# F5881) with additional *Mtb* (BD
363 Difco, Cat# 231141; 200 μ g/mouse). The mice also received an intraperitoneal injection of
364 Pertussis toxin (PTx) (200ng/mouse) (List Biological Technologies, Cat# 180) on Day 0 and 2.
365 Unless otherwise noted, we induced EAE with this method, as "Type-A EAE" (100 μ g MOG<sub>35-
366 55</sub>/mouse and 200 μ g *Mtb*/mouse)(9). In some experiments, "Type-B EAE" (9) was induced with
367 CFA/MOG injection on day 0 and 7 (100 μ g MOG₃₅₋₅₅/mouse, 400 μ g *Mtb*/mouse) and PTx (200
368 ng/mouse) on day 0, 2, and 7. EAE was scored as previously described (2, 3, 9).

369

370 **Preparation of frozen tissue sections and staining with antibodies.** Animals were lethally
371 anesthetized with 100 mg/kg of Nembutal administered intraperitoneally and transcardially
372 perfused with PBS and subsequently 4% paraformaldehyde (PFA)(Sigma-Aldrich, Cat# 158127).
373 SC and iLNs were harvested and fixed for 24 hours at 4°C in 4% PFA. All tissues were

374 cryoprotected in 30% sucrose in water for an additional 24 hours before embedding and freezing
375 in Tissue-Tek O.C.T. compound (Sakura, Cat# 4583) on dry ice. Tissues were sectioned using a
376 Cryostar NX50 (Thermo Fisher Scientific) at a thickness of 25 μm and rendered as floating
377 sections. Sections were permeabilized with 0.25 % Triton X100 (Amresco, Cat# 0694-1L) and
378 blocked using 2% bovine serum albumin (GeminiBio / Cat# 700-101P). After antibody staining,
379 sections were mounted onto slides with ProLong™ Gold Antifade Mountant (Invitrogen, Cat#
380 P36931) or ProLong™ Gold Antifade Mountant with DAPI (Invitrogen, Cat# P36930). TUNEL
381 staining was also performed with 25 μm thick floating tissue sections with the CF 640R TUNEL
382 Assay Apoptosis Detection Kit (Biotium, Cat# 30074). Antibodies used for staining are indicated
383 in **Supplementary Table 1**.

384
385 **Preparation of tissue slice culture and anti-ASC immunostaining.** Spleens were dissected
386 out of mice, and live spleen slices were prepared with a vibratome (Precisionary Compresstome)
387 using 4% low melt agarose as described by manufacturer's protocol. Slices in complete RPMI
388 were kept as floating sections and treated with 100 ng/mL Ultrapure LPS (Invivogen, Cat# tlr1-
389 3pelps) for 2 hours followed by 5 μM nigericin (Sigma-Aldrich, Cat# N7143) for additional 1 hour.
390 After fixation and permeabilization with ice cold methanol for 15 minutes, slices were blocked with
391 2% BSA in PBS for 1 hour at RT. Immunofluorescence staining was performed with antibodies
392 listed in **Table S1**.

393
394 **Immunofluorescence microscopy and image analyses.** All slides were imaged on the Zeiss
395 710 Inverted Laser Scanning Confocal Microscope (Duke University Light Microscopy Core
396 Facility) at full 25 μm depth as z-stacks. For quantifications, 2 sections per animal were imaged,
397 and a 2x2 grid tile scan was performed using the 20x objective centered on the ventral horn of
398 the SC, totaling 8 fields per mouse. Following quantification, these replicates were averaged to
399 generate a single n for statistical analyses. Semi-automated quantification was conducted using
400 the Imaris for Neuroscientists Cell Imaging Software ver. 9.3.0. (Bitplane) unless otherwise
401 indicated. Briefly, the Surfaces tool was used to identify either ASC specks/strings or cells, and
402 intensity thresholds of counterstain signals within the surfaces were used to quantify the desired
403 characteristics. ASC specks and ASC strings counts in **Fig. 1** were manually enumerated using
404 the LSM Browser software (Zeiss).

405
406 **Bone Marrow Chimeras.** Recipient mice (CD45.2; 6-8 weeks old) were lethally irradiated with
407 900 rad (XRAD 320 X-Ray irradiator) and adoptively transferred with 10^6 CD45.1 donor bone
408 marrow (BM) cells. Mice were supported with water containing sulfamethoxazole and
409 trimethoprim for 1 week following irradiation. At 6 weeks post-adoptive transfer, the donor cell
410 reconstitution was confirmed by differential expression of congenic markers in peripheral blood
411 using the BD FACSCanto II (BD Biosciences).

412
413 **Tamoxifen pulse for selective microglial labeling.** This procedure was adapted from previous
414 work (50). Briefly, mice with *Cx3cr1^{CreERT2}* (6-8 weeks old) received an intraperitoneal injection of
415 75 mg/kg tamoxifen dissolved in corn oil. The second injection with the same formula was
416 administered two days later. Mice were kept for six weeks after the last tamoxifen administration
417 for six weeks before EAE induction.

418
419 **Astrocyte isolation and RT-qPCR.** Astrocytes were isolated as previously described (51) with a
420 few modifications. Briefly, mouse SC were minced into $\sim 1\text{mm}^2$ pieces and digested using the
421 Papain Dissociation System (Worthington Biochemical Corporation, Cat# LK003153). Isolated
422 cells were negatively selected tandemly first with Myelin Removal Beads II (Miltenyi Biotec, Cat#
423 130-096-731) and second with anti-CD11b MicroBeads (Miltenyi Biotec, Cat# 130-049-601) to
424 collect the flowthrough fraction. To enrich astrocytes, the flowthrough cells were first treated with

425 FcBlock (Miltenyi Biotec, Cat# 130-092-575), then positively selected using anti-ACSA-2
426 MicroBeads (Miltenyi Biotec, Cat# 130-097-678). Total RNA was prepared using TRI Reagent
427 (Millipore-Sigma, Cat# 93289) and reverse-transcribed using qScript cDNA Mix (Quantabio, Cat#
428 950048) to obtain cDNA. RT-qPCR assays were performed with SYBR FAST qPCR Master Mix
429 (Kapa Biosystems, Cat# KK4602), using primers indicated in **Supplementary Table 2**.
430 Expression levels of target genes relative to an internal control, *Actb*, were calculated using the –
431 $\Delta\Delta C_t$ method (52).

432
433 **Cell culture and Western blotting analysis.** BMDMs were generated by culturing total BM cells
434 for 7 days in complete RPMI supplemented with 10 ng/mL recombinant mouse M-CSF
435 (BioLegend, Cat# 576406M-CSF). C8-S cells (ATCC, Cat# CRL-2535) were cultured in complete
436 DMEM. One day before stimulation, BMDMs and C8-S cells were seeded into poly-L-lysine-
437 coated 12-well plates (1.5×10^6 cells/well). Then, cells were pre-treated with 100 ng/mL Ultrapure
438 LPS (Invivogen, Cat# tlr-3pelps) in serum-free Opti-MEM medium (Thermo Fisher Scientific, Cat#
439 11058021) for 2 hours and stimulated with 5 μ M nigericin (Sigma-Aldrich, Cat# N7143) or
440 poly(dA:dT) (InvivoGen, Cat# tlr-patn) for 4 hours to activate the NLRP3 and AIM2
441 inflammasomes, respectively. Poly(dA:dT) was used as a complex with Lipofectamine 2000
442 (InvitroGen, Cat# 11668019) at a concentration of 0.5 μ g/mL. Culture supernatants and cell
443 lysates (in RIPA buffer) were harvested and, total protein concentrations were quantified using
444 the BCA Protein Assay Kit (ThermoFisher Scientific, Cat# 23227). The same amount of total
445 protein was used across all samples for SDS-PAGE gel separation. Western blotting (WB) was
446 performed with indicated antibodies (**Supplementary Table 1**), and the result was imaged using
447 the GeneGnome Chemiluminescence System (Syngene) and the Genesys (Syngene) software.
448 Band intensity was quantified using the Genetools (Syngene) Software. Lysate β -actin band
449 intensity was used to normalize both the lysate and supernatant band intensity.

450 451 **Statistical Analyses**

452 Area under the curve (AUC) values were used to statistically analyze EAE scoring data. The
453 Mann-Whitney U-test was used to compare between two groups, unless otherwise indicated. Pre-
454 peak and post-peak AUC were defined by identifying the dpi at which disease score ceased to
455 increase or began to decrease for both groups in a single experiment. All other analyses, where
456 indicated in the figure legend, were performed using either the Mann-Whitney U-test, a One-
457 Factor ANOVA, or a Two-Factor ANOVA. Post-hoc testing was performed only if ANOVA reached
458 significance on interaction term ($p < 0.1$). The Dunnett's Multiple Comparisons and the Sidak's
459 multiple comparisons were conducted post-hoc where indicated in the figure legend. All statistical
460 analyses were performed using the Graphpad Prism 8 software.

461
462
463 **Author Contributions:** W.E.B., M.E.D., and M.L.S. designed research; W.E.B., M.E.D., M.I.,
464 T.N., K.N., N.A.L., and N.A. performed experiments, W.E.B. M.E.D., and M.L.S. analyzed data;
465 W.E.B. and M.L.S wrote the manuscript; and M.E.D., M.I., K.N., N.A.L., N.A. and E.A.M. edited
466 the manuscript.

467
468 **Competing Interest Statement:** The authors declare no competing interest.

469
470 **Data Availability:** All study data are included in the article and/or *SI Appendix*.

471
472 **Acknowledgements:** We appreciate Dr. Golenbock for his generous gift of a mutant mouse
473 strain and for sharing unpublished data. We also appreciate Dr. Cagla Eroglu and Maria Pia
474 Rodriguez Salazar for their advice on handling astrocytes. We appreciate Dr. Ryan Finethy for
475 his advice on inflammasome immunostaining protocols. We also appreciate Tomoko Kadota and

476 Amesha Crudup for their help in mouse maintenance. This study was funded to M.L.S. by National
477 Multiple Sclerosis Society (NMSS) Research Grant (RG 4536B2/1), NIH (R01-NS120417, R01-
478 AI088100), and the Chancellor's Discovery Program Research Fund at Duke University School
479 of Medicine.

480

481 **Footnotes:**

482 [✉](#)¹To whom correspondence may be addressed. Email: mari.shinohara@duke.edu

483 **AIM2**

484

485

486

487 **REFERENCES**

488

- 489 1. P. Broz, V. M. Dixit, Inflammasomes: mechanism of assembly, regulation and signalling. *Nat Rev*
490 *Immunol* **16**, 407-420 (2016).
- 491 2. M. Inoue, K. L. Williams, M. D. Gunn, M. L. Shinohara, NLRP3 inflammasome induces
492 chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis.
493 *Proc Natl Acad Sci U S A* **109**, 10480-10485 (2012).
- 494 3. M. Inoue *et al.*, Interferon-beta therapy against EAE is effective only when development of the
495 disease depends on the NLRP3 inflammasome. *Sci Signal* **5**, ra38 (2012).
- 496 4. D. Gris *et al.*, NLRP3 plays a critical role in the development of experimental autoimmune
497 encephalomyelitis by mediating Th1 and Th17 responses. *J Immunol* **185**, 974-981 (2010).
- 498 5. W. Barclay, M. L. Shinohara, Inflammasome activation in multiple sclerosis and experimental
499 autoimmune encephalomyelitis (EAE). *Brain Pathol* **27**, 213-219 (2017).
- 500 6. L. Vidmar *et al.*, Multiple Sclerosis patients carry an increased burden of exceedingly rare genetic
501 variants in the inflammasome regulatory genes. *Sci Rep* **9**, 9171 (2019).
- 502 7. S. Malhotra *et al.*, NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis
503 patients. *Mult Scler* **24**, 1507-1510 (2018).
- 504 8. S. Malhotra *et al.*, NLRP3 inflammasome as prognostic factor and therapeutic target in primary
505 progressive multiple sclerosis patients. *Brain* 10.1093/brain/awaa084 (2020).
- 506 9. M. Inoue *et al.*, An interferon-beta-resistant and NLRP3 inflammasome-independent subtype of
507 EAE with neuronal damage. *Nat Neurosci* **19**, 1599-1609 (2016).
- 508 10. M. T. Heneka *et al.*, NLRP3 is activated in Alzheimer's disease and contributes to pathology in
509 APP/PS1 mice. *Nature* **493**, 674-678 (2013).
- 510 11. B. Hou *et al.*, Inhibition of the NLRP3-inflammasome prevents cognitive deficits in experimental
511 autoimmune encephalomyelitis mice via the alteration of astrocyte phenotype. *Cell Death Dis* **11**,
512 377 (2020).
- 513 12. C. R. Lammert *et al.*, AIM2 inflammasome surveillance of DNA damage shapes
514 neurodevelopment. *Nature* **580**, 647-652 (2020).
- 515 13. C. Ma *et al.*, AIM2 controls microglial inflammation to prevent experimental autoimmune
516 encephalomyelitis. *J Exp Med* **218** (2021).
- 517 14. B. A. McKenzie *et al.*, Activation of the executioner caspases-3 and -7 promotes microglial
518 pyroptosis in models of multiple sclerosis. *J Neuroinflammation* **17**, 253 (2020).
- 519 15. B. A. McKenzie *et al.*, Caspase-1 inhibition prevents glial inflammasome activation and pyroptosis
520 in models of multiple sclerosis. *Proc Natl Acad Sci U S A* **115**, E6065-E6074 (2018).

- 521 16. T. Zeis *et al.*, Metabolic gene expression changes in astrocytes in Multiple Sclerosis cerebral
522 cortex are indicative of immune-mediated signaling. *Brain Behav Immun* **48**, 313-325 (2015).
- 523 17. L. Freeman *et al.*, NLR members NLRC4 and NLRP3 mediate sterile inflammasome activation in
524 microglia and astrocytes. *J Exp Med* **214**, 1351-1370 (2017).
- 525 18. T. C. Tzeng *et al.*, A Fluorescent Reporter Mouse for Inflammasome Assembly Demonstrates an
526 Important Role for Cell-Bound and Free ASC Specks during In Vivo Infection. *Cell Rep* **16**, 571-
527 582 (2016).
- 528 19. G. C. Furtado *et al.*, Swift entry of myelin-specific T lymphocytes into the central nervous system
529 in spontaneous autoimmune encephalomyelitis. *J Immunol* **181**, 4648-4655 (2008).
- 530 20. M. van Zwam *et al.*, Surgical excision of CNS-draining lymph nodes reduces relapse severity in
531 chronic-relapsing experimental autoimmune encephalomyelitis. *J Pathol* **217**, 543-551 (2009).
- 532 21. M. J. C. Jordao *et al.*, Single-cell profiling identifies myeloid cell subsets with distinct fates during
533 neuroinflammation. *Science* **363** (2019).
- 534 22. R. Brambilla, The contribution of astrocytes to the neuroinflammatory response in multiple
535 sclerosis and experimental autoimmune encephalomyelitis. *Acta Neuropathol* **137**, 757-783
536 (2019).
- 537 23. G. Ponath, C. Park, D. Pitt, The Role of Astrocytes in Multiple Sclerosis. *Front Immunol* **9**, 217
538 (2018).
- 539 24. M. Pekny, M. Pekna, Astrocyte reactivity and reactive astrogliosis: costs and benefits. *Physiol*
540 *Rev* **94**, 1077-1098 (2014).
- 541 25. M. V. Sofroniew, H. V. Vinters, Astrocytes: biology and pathology. *Acta Neuropathol* **119**, 7-35
542 (2010).
- 543 26. S. A. Liddelow *et al.*, Neurotoxic reactive astrocytes are induced by activated microglia. *Nature*
544 **541**, 481-487 (2017).
- 545 27. N. Itoh *et al.*, Cell-specific and region-specific transcriptomics in the multiple sclerosis model:
546 Focus on astrocytes. *Proc Natl Acad Sci U S A* **115**, E302-E309 (2018).
- 547 28. F. Haroon *et al.*, Gp130-dependent astrocytic survival is critical for the control of autoimmune
548 central nervous system inflammation. *J Immunol* **186**, 6521-6531 (2011).
- 549 29. W. C. Chou *et al.*, AIM2 in regulatory T cells restrains autoimmune diseases. *Nature*
550 10.1038/s41586-021-03231-w (2021).
- 551 30. C. J. Zhang *et al.*, TLR-stimulated IRAKM activates caspase-8 inflammasome in microglia and
552 promotes neuroinflammation. *J Clin Invest* **128**, 5399-5412 (2018).
- 553 31. A. Pronin *et al.*, Inflammasome Activation Induces Pyroptosis in the Retina Exposed to Ocular
554 Hypertension Injury. *Front Mol Neurosci* **12**, 36 (2019).
- 555 32. A. C. Sahillioglu, F. Sumbul, N. Ozoren, T. Haliloglu, Structural and dynamics aspects of ASC
556 speck assembly. *Structure* **22**, 1722-1734 (2014).
- 557 33. M. Moriya *et al.*, Role of charged and hydrophobic residues in the oligomerization of the PYRIN
558 domain of ASC. *Biochemistry* **44**, 575-583 (2005).
- 559 34. A. Lu *et al.*, Unified polymerization mechanism for the assembly of ASC-dependent
560 inflammasomes. *Cell* **156**, 1193-1206 (2014).
- 561 35. F. I. Schmidt *et al.*, A single domain antibody fragment that recognizes the adaptor ASC defines
562 the role of ASC domains in inflammasome assembly. *J Exp Med* **213**, 771-790 (2016).
- 563 36. N. B. Bryan *et al.*, Differential splicing of the apoptosis-associated speck like protein containing a
564 caspase recruitment domain (ASC) regulates inflammasomes. *Journal of inflammation (London,*
565 *England)* **7**, 23 (2010).

- 566 37. A. Viedma-Poyatos, Y. de Pablo, M. Pekny, D. Perez-Sala, The cysteine residue of glial fibrillary
567 acidic protein is a critical target for lipoxidation and required for efficient network organization.
568 *Free Radic Biol Med* **120**, 380-394 (2018).
- 569 38. G. dos Santos *et al.*, Vimentin regulates activation of the NLRP3 inflammasome. *Nat Commun* **6**,
570 6574 (2015).
- 571 39. S. Shalini, L. Dorstyn, S. Dawar, S. Kumar, Old, new and emerging functions of caspases. *Cell*
572 *Death Differ* **22**, 526-539 (2015).
- 573 40. A. Erturk, Y. Wang, M. Sheng, Local pruning of dendrites and spines by caspase-3-dependent
574 and proteasome-limited mechanisms. *J Neurosci* **34**, 1672-1688 (2014).
- 575 41. D. J. Simon *et al.*, A caspase cascade regulating developmental axon degeneration. *J Neurosci*
576 **32**, 17540-17553 (2012).
- 577 42. Z. Li *et al.*, Caspase-3 activation via mitochondria is required for long-term depression and AMPA
578 receptor internalization. *Cell* **141**, 859-871 (2010).
- 579 43. P. E. Mouser, E. Head, K. H. Ha, T. T. Rohn, Caspase-mediated cleavage of glial fibrillary acidic
580 protein within degenerating astrocytes of the Alzheimer's disease brain. *Am J Pathol* **168**, 936-
581 946 (2006).
- 582 44. L. Acarin *et al.*, Caspase-3 activation in astrocytes following postnatal excitotoxic damage
583 correlates with cytoskeletal remodeling but not with cell death or proliferation. *Glia* **55**, 954-965
584 (2007).
- 585 45. R. Aras, A. M. Barron, C. J. Pike, Caspase activation contributes to astrogliosis. *Brain Res* **1450**,
586 102-115 (2012).
- 587 46. S. Villapol, L. Acarin, M. Faiz, B. Castellano, B. Gonzalez, Survivin and heat shock protein 25/27
588 colocalize with cleaved caspase-3 in surviving reactive astrocytes following excitotoxicity to the
589 immature brain. *Neuroscience* **153**, 108-119 (2008).
- 590 47. B. Hu *et al.*, The DNA-sensing AIM2 inflammasome controls radiation-induced cell death and
591 tissue injury. *Science* **354**, 765-768 (2016).
- 592 48. A. Di Micco *et al.*, AIM2 inflammasome is activated by pharmacological disruption of nuclear
593 envelope integrity. *Proc Natl Acad Sci U S A* **113**, E4671-4680 (2016).
- 594 49. A. Dumas *et al.*, The inflammasome pyrin contributes to pertussis toxin-induced IL-1beta
595 synthesis, neutrophil intravascular crawling and autoimmune encephalomyelitis. *PLoS Pathog* **10**,
596 e1004150 (2014).
- 597 50. E. G. O'Koren, R. Mathew, D. R. Saban, Fate mapping reveals that microglia and recruited
598 monocyte-derived macrophages are definitively distinguishable by phenotype in the retina. *Sci*
599 *Rep* **6**, 20636 (2016).
- 600 51. L. M. Holt, S. T. Stoyanof, M. L. Olsen, Magnetic Cell Sorting for In Vivo and In Vitro Astrocyte,
601 Neuron, and Microglia Analysis. *Curr Protoc Neurosci* **88**, e71 (2019).
- 602 52. K. J. Livak, T. D. Schmittgen, Analysis of relative gene expression data using real-time
603 quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* **25**, 402-408 (2001).

604

605 Figure Legends

606

607 **Figure 1. Inflammasome activation in the CNS during late EAE (A)** EAE disease score of WT
608 ($n=5$) vs. ASC-Citrine mice ($n=4$). Mann-Whitney test of total AUC for disease was used. **(B, C)**
609 Representative images **(B)** and quantification **(C)** of ASC specks in the iLNs of ASC-Citrine mice
610 during EAE. Each datapoint represents a value of an average value from two cross-sections of
611 both iLNs (25 μm thickness) per mouse. $n=5$ mice. One-way ANOVA, $p=0.0006$, with Dunnett's
612 multiple comparisons test. Scale bar is 20 μm . **(D)** Representative images of SC from ASC-Citrine
613 mice at indicated time points during EAE. Scale bar is 300 μm . **(E-H)** Representative image **(E,**
614 **G)** and quantification **(F, H)** of ASC specks **(E, F)** and ASC strings **(G, H)** in SC from ASC-Citrine
615 mice during EAE. Scale bar is 10 μm . Each datapoint represents a value from one mouse ($n=5$).
616 Two coronal cross-sections (25 μm thickness) of L5 SC from one mouse were quantified manually
617 and averaged. One-way ANOVA with Dunnett's multiple comparisons tests **(C, F, H)**. $^{ns} p>0.05$,
618 $^{**} p < 0.01$, $^{***} p < 0.001$, $^{****} p < 0.0001$. Error bars denote mean \pm SEM.

619

620 **Figure 2. No inflammasome activation in hematopoietic cells in the CNS during EAE. (A)**
621 EAE disease scores of WT (BM donor) \rightarrow WT (recipient) chimeras vs. WT \rightarrow *Pycard*^{-/-} chimeras.
622 $n=7$, combined from multiple experiments. **(B, C)** Comparison of EAE disease severity of
623 WT \rightarrow WT chimeras versus WT \rightarrow *Pycard*^{-/-} chimeras. Each datapoint represents a value from one
624 mouse ($n=7$), combined from multiple experiments. Area under curve (AUC) quantification of pre-
625 peak disease **(B)**, AUC quantification of post-peak disease **(C)**. **(D, E)** Representative images **(D)**
626 and quantification **(E)** of ASC specks in the iLNs of WT \rightarrow ASC-Citrine chimeras versus ASC-
627 Citrine \rightarrow WT chimeras at 3 dpi of EAE. Each datapoint represents a value from one mouse as an
628 average of both iLNs ($n=4$). Mann-Whitney test was used. Scale bar is 20 μm . **(F-H)**
629 Representative images **(F)** and quantification of ASC specks **(G)** and ASC strings **(H)** of SC from
630 WT \rightarrow ASC-Citrine BM chimeras ($n=4$) versus ASC-Citrine \rightarrow WT chimeras ($n=6$) at 30-dpi of EAE.
631 Each datapoint represents a value from one mouse. Mann-Whitney test was used **(B, C, E, G, H)**.
632 Scale bar is 300 μm . **(B, C, G, H)**. $^{ns} p>0.05$, $^{*} p < 0.05$, $^{**} p < 0.01$, $^{***} p < 0.001$. Error bars denote
633 mean \pm SEM.

634

635 **Figure 3. Identifying inflammasome activation in CNS cells with an immunofluorescent**
636 **approach. (A-C)** Representative images of ASC specks and strings counter-stained with
637 antibodies against TMEM119 for microglia **(A)**, GFAP for astrocytes **(B)**, and NeuN for neurons
638 **(C)** in SC from naïve versus 30-dpi EAE ASC-Citrine mice. Scale bar is 20 μm . **(D, E)**
639 Quantification of ASC specks **(D)** and ASC strings **(E)** in microglia, astrocytes, and neurons in the
640 ventral horn (VH) of SC from naïve versus 30-dpi EAE ASC-Citrine mice. Two-way repeated
641 measures (RM) ANOVAs were used (main effect of cell type: $^{****} p < 0.0001$ **(D, E)**), with Sidak's
642 multiple comparisons test post hoc ($^{#} p < 0.05$, $^{##} p < 0.01$). **(F)** Relative contribution of microglia,
643 astrocytes and neurons to total number of ASC specks in L5 SC at 30-dpi EAE. "Unassigned"
644 indicates unidentified cell sources of ASC-Citrine signals. Each datapoint represents a value
645 from one mouse ($n=5$). Two-way RM ANOVA was used (main effect of cell type: $p < 0.001$) with
646 Sidak's multiple comparisons test post hoc. $^{**} p < 0.01$. Error bars denote mean \pm SEM.

647

648 **Figure 4. Identifying Inflammasome activation in CNS cells by a mouse genetics approach.**
649 **(A-C)** Representative images of SC in *Asc-Citrine*^{LSL} versus *Cx3cr1*^{CreERT2};*Asc-Citrine*^{LSL} mice **(A)**,
650 *Gfap*^{Cre/+};*Asc-Citrine*^{LSL} mice **(B)**, and *Syn1*^{Cre/+};*Asc-Citrine*^{LSL} mice **(C)** at day 30-dpi of EAE. Mice
651 for microglia evaluation were treated with tamoxifen. Scale bar is 20 μm . **(D, E)** Quantification of
652 ASC specks **(D)** and ASC strings **(E)** in SC VH of mice indicated in **(A-C)**. Each datapoint
653 represents a value from one mouse. Combined from multiple experiments. **(D, E)** Mann-Whitney
654 test was used. $^{****} p < 0.0001$. Error bars denote mean \pm SEM.

655
656 **Figure 5. Evaluation of astrocytes with activated inflammasomes. (A, B)** Representative
657 images (A) and quantification (B) of total GFAP intensity in SC ventral gray matter from naïve 30-
658 dpi EAE mice. Scale bar is 200 μm . GFAP intensity was quantified as mean signal intensity of
659 GFAP in the ventral grey matter (VGM) using ImageJ. Mann-Whitney test was used. **(C-E)**
660 Representative images (C) and quantification of GFAP intensity (D) and C3d intensity (E) per cell
661 in gray matter SC astrocytes with and without ASC specks/strings from naïve ASC-Citrine ($n=7$)
662 mice versus ASC-Citrine mice at 30-dpi of EAE ($n=6$). Scale bar is 200 μm . Each datapoint
663 represents a value from one mouse. Individual astrocytes were identified using the Imaris
664 software and the mean intensity per cell was quantified for GFAP and C3d. Two-way RM ANOVA
665 was used with Sidak's multiple comparisons test post-hoc. $**p<0.01$. $***p<0.001$. Error bars
666 denote mean \pm SEM.

667
668 **Figure 6. Outcomes of inflammasome activation in astrocytes. (A, B)** RT-qPCR evaluation
669 of inflammasome-related genes in SC total cells vs. astrocytes isolated from mice with EAE at 30-
670 dpi. Two-way RM ANOVAs were used with Sidak's multiple comparisons test post-hoc. **(C)**
671 Representative images of Western blotting for inflammasome components in BMDMs vs. C8-S
672 cells. Cells in all groups were pre-treated with Ultrapure LPS. Groups in Lane 2 and 3 were further
673 stimulated with nigericin and poly(dA:dT)/liposome to activate the NLRP3 and AIM2
674 inflammasomes, respectively. (Cells in Group1 were treated by Ultrapure LPS alone.) **(D, E)**
675 Representative images (D) and quantification (E) of TUNEL staining of SC sections from naïve
676 ($n=3$) and 30-dpi EAE ASC-Citrine mice ($n=4$). Two-way repeated measures (RM) ANOVAs was
677 used. Scale bar is 75 μm . **(F, G)** Representative images (F) and quantification (G) of active
678 caspase-3 (CC3) in SC astrocytes with and without ASC specks/strings. Evaluated from naïve
679 ($n=7$) and at 30-dpi EAE ($n=6$) ASC-Citrine mice. Scale bar is 200 μm . Individual astrocytes were
680 identified using the Imaris software and were quantified by CC3 puncta staining. Each datapoint
681 represents a value from one mouse, combined from multiple experiments. Two-way RM ANOVA
682 was used with Sidak's multiple comparison test post-hoc. (A, B, E, G) $**p<0.01$, $***p<0.001$,
683 $****p<0.0001$. Error bars denote mean \pm SEM.

684
685 **Figure 7. AIM2 inflammasome activation in astrocytes during EAE. (A, B)** Comparison of
686 ASC speck formation in indicated mouse groups. Representative images (A) and quantification
687 of ASC specks (B) of SC sections from ASC-Citrine ($n=6$) versus *Nlrp3*^{-/-} ASC-Citrine ($n=7$) mice
688 at 30-dpi Type B EAE. Mann-Whitney test was used. **(C, D)** EAE disease scores (C) and statistical
689 evaluation of AUC (D) of WT ($n=8$) versus *Aim2*^{-/-} ($n=7$) mice induced with Type-A EAE with low
690 dose *Mtb* (50 $\mu\text{g}/\text{mouse}$). Mann-Whitney test of AUC was used to analyze post-peak disease (D).
691 **(E)** Quantification of GFAP intensity per cell in gray matter SC astrocytes from WT ($n=3$) versus
692 *Aim2*^{-/-} ($n=4$) mice at 30-dpi of Type-A EAE with low dose *Mtb* (50 $\mu\text{g}/\text{mouse}$). Unpaired t-test was
693 used. **(F-H)** Type-A EAE with 200 μg *Mtb*/mouse. EAE disease score of ASC-Citrine ($n=8$), *Aim2*^{-/-}
694 ;ASC-Citrine ($n=6$), *Aim2*^{-/-}; ASC-Citrine ($n=4$) mice (F). Representative images (G) and
695 quantification of ASC specks (H) of SC sections at 30-dpi EAE. Scale bar is 200 μm (A, G). One-
696 way ANOVA was used ($p < 0.0001$) with Dunnet's multiple comparisons test post-hoc (H).
697 Unpaired t-test was used. (B,D,E). Each datapoint represents a value from one mouse (B, D, E,
698 H). *ns*; not significant ($p>0.05$), $*p<0.05$, $**p<0.01$. Error bars denote mean \pm SEM.

699
700 **Figure S1. Validation of ASC-Citrine system in tissue imaging. (A)** Representative images of
701 ASC speck formation detected with ASC-Citrine and ASC antibody signals. Live spleen tissue
702 culture slices from naïve WT and ASC-Citrine mice were used with NLRP3 inflammasome
703 stimulation. Scale bar is 50 μm . **(B)** Quantification of ASC specks in the iLNs and cLNs of ASC-
704 Citrine mice during EAE. Each datapoint represents a value of an average value from two cross-

705 sections of LNs (25 μm thickness) from one mouse. One-way ANOVA, $p=0.0021$ (iLN), $p=0.3235$
706 (cLN), with Dunnett's multiple comparisons test. **(C, D)** Comparison of ASC speck images and
707 numbers in SC between Type-A and Type-B EAE. Representative images (C) and quantification
708 (D) of ASC specks in the SC of ASC-Citrine mice at 30-dpi for Type A ($n=5$) and Type B ($n=8$)
709 EAE. Each datapoint represents a value from one mouse. Mann-Whitney test was used. Scale
710 bar is 200 μm . **(B,D)** *ns*; not significant ($p>0.05$), $*p<0.05$, $**p<0.01$. Error bars denote mean \pm
711 SEM.

712

713 **Figure S2. Validation of Bone Marrow Chimeras.** BM chimera were created by transferring WT
714 BM cells to irradiated WT or *Pycard*^{-/-} recipients ($n=7$ for each group). Reconstitution efficiency
715 of BM chimeras determined by flow cytometry, quantified as % of total CD45⁺ cells in peripheral
716 blood for congenic markers of CD45.1 (donor) or CD45.2 (recipient). Each datapoint represents
717 a value from one mouse. Mann-Whitney test used. **(B, C)** BM chimera were created by
718 transferring ASC-Citrine BM cells irradiated WT recipients (ASC-Citrine \rightarrow WT, $n=6$) and vice
719 versa (WT \rightarrow ASC-Citrine mice, $n=8$). Reconstitution efficiency (B) and EAE disease score (C) of
720 indicated BM chimera Mann-Whitney test of total AUC for disease. **(D)** Representative images of
721 SC from ASC-Citrine \rightarrow WT mice at indicated time points during EAE. No apparent ASC specks
722 were observed. Scale bar is 500 μm . **(E)** Representative image of ALDH1L1 counterstaining of
723 astrocytes in ASC-Citrine mice at 30-dpi EAE. Scale bar is 10 μm . **(F)** Representative images of
724 ASC specks and strings counter-stained with antibodies against NG2 (for OPCs) and MBP (for
725 mature oligodendrocytes) in SC from naïve versus 30-dpi EAE ASC-Citrine mice. Scale bar is 20
726 μm . **(G)** Quantification of ASC specks in OPCs and mature oligodendrocytes of SC from naïve
727 versus 30-dpi EAE ASC-Citrine mice. Each datapoint represents a value from one mouse. Two-
728 way repeated measures (RM) ANOVA was used (main effect of cell type: ^{ns} $p<0.7807$). **(H)**
729 Percentages of ASC specks detected in OPC or mature oligodendrocytes out of total ASC specks
730 per section, indicating relative contribution of OPCs and oligodendrocyte ASC specks to total
731 number of ASC specks in L5 spinal cord at 30-dpi EAE. **(A,B,C,G,H)** *ns*; not significant ($p>0.05$).
732 Error bars denote mean \pm SEM. **(I)** Percentage of ChAT⁺ and ChAT⁻ VH neurons containing
733 ASC specks in SC from naïve vs. 30-dpi EAE ASC-Citrine mice. Each datapoint represents a
734 value from one mouse ($n=5$). Two-way RM ANOVA was used (main effect of cell type: $p<0.001$)
735 with Sidak's multiple comparisons test post hoc. $**p<0.01$.

736

737 **Figure S3. Validation of EAE mice with cell type-specific ASC-Citrine expression.** **(A)**
738 Tamoxifen mediated expression of ASC-citrine reporter expression in microglia and splenic
739 monocytes in *Cx3cr1*^{CreERT2};*Asc-Citrine*^{LSL} with or without tamoxifen (TAM) treatment. **(B)** Flow
740 cytometry gating strategy for identifying microglia. **(C)** EAE disease score of *Cx3cr1*^{CreERT2};*Asc-*
741 *Citrine*^{LSL} ($n=5$) vs. *Cx3cr1*^{CreERT2};*Asc-Citrine*^{LSL} ($n=5$). Both groups were treated with TAM. **(D, E)**
742 EAE disease score of *Asc-Citrine*^{LSL} ($n=10$) vs. *Gfap*^{Cre};*Asc-Citrine*^{LSL} ($n=13$) (D) and *Asc-*
743 *Citrine*^{LSL} ($n=13$) vs. *Syn1*^{Cre};*Asc-Citrine*^{LSL} ($n=10$) (E). Mann-Whitney test of total AUC of disease
744 score was used (C,D,E). *ns*; not significant ($p>0.05$). Error bars denote mean \pm SEM.

745


746 **Figure S4. Expression of inflammasome components and cell death markers in astrocytes**
747 **during EAE.** **(A)** Gene-set enrichment analysis of inflammasome-associated genes in bulk SC
748 lysates and astrocytes (with astrocyte-specific Ribotag-HA enriched RNA) in naïve and 30-dpi
749 EAE mice. Data represented as raw transcript counts derived from publicly available data (GEO
750 Accession #: GSE100329). **(B-G)** Representative images (B-D) and quantification (E-F) of
751 caspase-1 (B, E), IL-1 β (C, F), and GSDMD (D, G) expression in spleen and SC astrocytes from

752 naïve versus 30-dpi EAE ASC-Citrine mice. Scale bar is 20 μm . Each datapoint represents a
753 value from one mouse. Individual astrocytes were identified using the Imaris software and the
754 mean intensity per cell was quantified for caspase-1 (E), IL-1 β (F) and GSDMD (G). Mann-
755 Whitney test was used. (E-G) *ns*; not significant ($p>0.05$). Error bars denote mean \pm SEM.

756
757 **Figure S5. Expression of inflammasome components in C8-S astrocyte cell line (A-C)** WB
758 quantitative evaluation of culture supernatant samples of mature caspase-1 (A), IL-1 β (B), and IL-
759 18 (C). **(D-H)** WB quantitative evaluation of cell lysate samples of pro-caspase-1 (D), pro-IL-1 β
760 (E), pro-IL-18 (F), GSDMD-FL (G), and GSDMD-NT (H). In (A-H), all groups were stimulated with
761 Ultrapure LPS, and Groups 2 and 3 were further stimulated with nigericin and
762 poly(dA:dT)/liposome to activate the NLRP3 and AIM2 inflammasomes, respectively. (Thus,
763 Group 1 has Ultrapure LPS treatment alone.) Each datapoint is obtained from one independent
764 experiment. Two-way RM ANOVA was used with Sidak's multiple comparison test post-hoc. **(I)**
765 Quantification of active caspase-3 (CC3) in spinal cord astrocytes with and without ASC
766 specks/strings in *Gfap*^{Cre};*Asc-Citrine*^{LSL} ($n=6$) mice at 30-dpi EAE. Each datapoint represents a
767 value from one mouse. Individual astrocytes were identified using the Imaris software and were
768 quantified by CC3 puncta staining. Mann-Whitney test was used. (A-I) ** $p<0.01$, ** $p<0.005$,
769 *** $p<0.001$, **** $p<0.0001$. Error bars denote mean \pm SEM.


770
771 **Figure S6. Validation of EAE phenotype of *Nlrp3*^{-/-};ASC-Citrine mice and immune**
772 **phenotype of *Aim2*^{-/-} mice with EAE. (A)** EAE disease score of ASC-Citrine ($n=7$) vs. *Nlrp3*^{-/-}
773 ;ASC-Citrine ($n=8$) mice with Type B-EAE. Mann-Whitney test of total AUC for disease score was
774 used. **(B–D)** Leukocyte counts in SC (B), iLN (C) and spleen (D) at 16-dpi EAE in WT vs. *Aim2*^{-/-}
775 mice induced with Type-A EAE. One datapoint represents a value from one mouse. Two-way RM
776 ANOVA was used with Sidak's multiple comparisons test post hoc. **(E)** Representative image of
777 GFAP staining in SC from WT versus *Aim2*^{-/-} mice at 30-dpi of EAE. Scale bar is 200 μm . (A-D)
778 *ns*; not significant ($p>0.05$). Error bars denote mean \pm SEM.

779
780



781
782

Figure 1




783

784


785

Figure 2




786
787
788
789
790
791
792
793
794
795
796

Figure 3



797
798
799
800
801
802
803
804
805
806
807
808
809
810
811


Figure 4



812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828

Figure 5


829



830

831

Figure 6



832
833
834
835

Figure 7




Figure S1




Figure S2




Figure S3




Figure S4




Figure S5




Figure S6

Table S1. Reagent information for antibody-based techniques

Target	Cat #	Species	Clone	Supplier	Dilution	Technique
ASC	AG-25B-0006-C100	Rabbit	AL177, polyclonal	Adipogen	1:500	IF Imaging
Tmem119	ab209064	Rabbit	28-3	Abcam	1:500	IF Imaging
GFAP	13-0300	Rat	2.2B10	Invitrogen	1:500	IF Imaging, Western Blotting
ALDHL1	ab87117	Rabbit	polyclonal	Abcam	1:500	IF Imaging
NeuN	ab104225	Rabbit	polyclonal	Abcam	1:500	IF Imaging
ChAT	AB144P	Goat	polyclonal	EMD Millipore	1:100	IF Imaging
NG2	ab275024	Rabbit	EPR23976-145	Abcam	1:500	IF Imaging
MBP	ab218011	Rabbit	EPR21188	Abcam	1:500	IF Imaging
Iba1	NB100-1028	Goat	polyclonal	Novus Biologicals	1:500	IF Imaging
C3d	AF2655	Goat	polyclonal	R&D Systems	1:500	IF Imaging
Cleaved caspase-3	9664S	Rabbit	5AIE	Cell Signaling Technologies	1:500	IF Imaging
Caspase-1	N/A	Rat	4b4	Genentech	1:500	IF Imaging, Western Blotting
Gasdermin D	PA5-1155330	Rabbit	polyclonal	ThermoFisher Scientific	1:500	IF Imaging
Gasdermin D	ab209845	Rabbit	EPR19828	Abcam	1:500	Western Blotting
IL-1 β	AF-401-NA	Goat	polyclonal	R&D Systems	1:1000	IF Imaging, Western Blotting
IL-18	210-401-323	Rabbit	polyclonal	Rockland	1:1000	Western Blotting
CD45.1	110708	Mouse	A20	Biolegend	1:200	Flow Cytometry
CD45.2	109831	Mouse	104	Biolegend	1:200	Flow Cytometry

Table S2. Sequences of primers used for RT-qPCR assays

Gene	Direction	Sequence
<i>Actb</i>	Forward	TGT TAC CAA CTG GGA CGA CA
	Reverse	CTG GGT CAT CTT TTC ACG GT
<i>Casp1</i>	Forward	GAA GGC CCA TAT AGA GAA AGA TTT TAT TG
	Reverse	GAC AGG ATG TCT CCA AGA CAC ATT
<i>Gsdmd</i>	Forward	GCG ATC TCA TTC CGG TGG ACA G
	Reverse	TTC CCA TCG ACG ACA TCA GAG AC
<i>Il1b</i>	Forward	CGC AGC AGC ACA TCA ACA AGA GC
	Reverse	TGT CCT CAT CCT GGA AGG TCC ACG
<i>Il18</i>	Forward	CAG GCC TGA CAT CTT CTG CAA
	Reverse	CTG ACA TGG CAG CCA TTG T